A Current Review of Targeted Therapeutics for Ovarian Cancer

Table 1

Current trials in ovarian/fallopian/peritoneal cancer.

Author	N	Prior lines	Platinum S/R^∗/first line	Regimen∗∗	RR:CR + PR	TTP/PFS median
Burger R et al. [7]	62	1-2	+/+	Single	21 %	PFS 4.7mo
Cannistra et al. [8]	44	2-3	+/+	Single	15.9%	PFS 4.4 mo
Garcia et al. [9]	70	1–3	+/+	Combo	24%	TTP 7.2 mo
Wright et al. [10]	23	2–15	−/+	Combo	35 %	TTP 5.6 mo
Chura et al. [11]	15	5–15	+/+	Combo	43 %	PFS 3.9 mo
Nimeiri et al. [12]	13	1–3	+/+	Combo	15 %	PFS 4.1 mo
Monk et al. [13]	32	2–10	−/+	Single	16 %	PFS 5.5 mo
Simpkins et al. [14]	25	2–12	−/+	Combo	28 %	TTP 9.0 mo
McGonigle et al. [15]	18	0–2	−/+	Combo	22%	PFS 3.8 mo
Azad et al. [17]	13	NR	NR	Combo	46%	NR
Micha et al. [16]	20	0	First line	Combo	80%	NR
Campos/Penson et al. [18, 19]	58	0	First line	Combo	75%	PFS:11mo

∗Enrolled patients: platinum sensitive/resistant/first line.
∗∗Single bevacizumab or combination therapy with cytotoxic or other biological agents.
NR: not reported.